18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease

Journal of Nuclear Medicine

Volumn 56, Issue 3, 2015, Pages 386-391

  Kobylecki, Christopher ^a,b   Langheinrich, Tobias ^a,b   Hinz, Rainer ^a   Vardy, Emma R L C ^a,c,d   Brown, Gavin ^a   Martino, María Elena ^a,e   Haense, Cathleen ^f   Richardson, Anna M ^b,g   Gerhard, Alexander ^a,b   Anton Rodriguez, Jose M ^a   Snowden, Julie S ^a,b   Neary, David ^a,b   Pontecorvo, Michael J ^h   Herholz, Karl ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Amyloid; Diagnosis; Frontotemporal dementia; PET

Indexed keywords

APOLIPOPROTEIN E4; FLORBETAPIR F 18; AMYLOID PROTEIN; ANILINE DERIVATIVE; APOLIPOPROTEIN E; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE;

ADULT; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; APOE EPSILON4 GENE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENOTYPE; GRAY MATTER; HOMOZYGOTE; HUMAN; IMAGE QUALITY; MALE; MEDICAL RESEARCH; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PARIETAL CORTEX; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE RATIO; WHITE MATTER; AGED; CASE CONTROL STUDY; CHEMISTRY; DIAGNOSTIC USE; GENETICS; MIDDLE AGED; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANILINE COMPOUNDS; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 84928125855     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.147454     Document Type: Article

References (30)

1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615-1621.
2. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
3. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123:484-498.
4. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952-962.
5. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184-188.
6. Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841-870.
7. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.
8. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205-1212.
9. Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35:100-106.
10. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034-2042.
11. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
12. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
13. Fleisher AS, Chen K, Liu X, et al. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1-12.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
15. Segobin S, Matthews J, Coope D, et al. Motion detection from raw list-mode HRRT data and improved frame-by-frame realignment for motion correction [abstract]. J Nucl Med. 2009;50:589.
16. Hong IK, Chung ST, Kim HK, Kim YB, Son YD, Cho ZH. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging. 2007;26:789-803.
17. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-247.
18. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med. 1991;14:9-30.
19. 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42:548-557.
20. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
21. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-1411.
22. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5, suppl):S72-S83.
23. Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain. 2011;134:2478-2492.
24. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
25. 18Fflorbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
26. Thomas BA, Erlandsson K, Modat M, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38:1104-1119.
27. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130:2636-2645.
28. Mann DM, McDonagh AM, Pickering-Brown SM, Kowa H, Iwatsubo T. Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett. 2001;304:161-164.
29. Serrano GE, Sabbagh MN, Sue LI, et al. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis. 2014;42:813-821.
30. Fodero-Tavoletti MT, Rowe CC, McLean CA, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198-204.